Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Tri-Point Medical

This article was originally published in The Gray Sheet

Executive Summary

Tri-Point Medical: Inks supply and distribution agreement under which Johnson & Johnson's Ethicon subsidiary gains worldwide marketing rights to its Traumaseal topical, nonabsorbable wound-closure adhesive product. The device began U.S. clinical trials in January ("The Gray Sheet" Jan. 15, In Brief) and the company anticipates completion of the studies this summer. The Raleigh, North Carolina-based firm hopes to submit a premarket approval application by year end. The deal includes "an up-front payment" and "cash advances on future purchases and milestone payments" upon FDA approval, the firm states. Terms were not disclosed...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel